Simulations Plus, Inc.
SLPNasdaq
$18.23
0.0%Jul 17 close · end-of-day
Price
1Y↑ +41.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$369.0M
Enterprise Value
$319.0M
P/E
45.6
P/S
4.5
P/B
2.7
EV/EBITDA
17.0
PEG
—
FCF Yield
6.7%
Dividend Yield
—
Revenue (TTM)
$82.1M
Net Income (TTM)
$8.1M
Free Cash Flow (TTM)
$24.5M
Gross Margin
63.4%
Operating Margin
14.0%
Net Margin
9.9%
ROE
5.8%
ROIC
8.3%
Debt / Equity
—
Net Cash
$50.0M
Return 1Y
+42.5%
Company profile
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym; IPFsym; RENAsym; MITOsym.
- CEO
- Shawn M. O'Connor
- Sector
- Manufacturing
- Industry
- Computer Software
- Employees
- 160
- Headquarters
- North Carolina
- Website
- simulations-plus.com
Earnings
SLP Q3 2026 Earnings
Period ends 2026-05-31
MetricActualYoY
Revenue$21.9M↑ +7.5%
Diluted EPS$0.18↓ -105.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.6M | $46.5M | $53.9M | $59.6M | $70.0M | $79.2M |
| Gross profit | $30.9M | $35.9M | $43.1M | $47.9M | $43.2M | $46.2M |
| Operating income | $11.6M | $11.3M | $14.9M | $8.7M | $6.1M | -$70.7M |
| Net income | $9.3M | $9.8M | $12.5M | $10.0M | $10.0M | -$64.7M |
| Diluted EPS | $0.50 | $0.47 | $0.60 | $0.49 | $0.49 | -$3.22 |
| Operating cash flow | $10.9M | $19.2M | $17.9M | $21.9M | $13.3M | $18.1M |
| Free cash flow | $10.7M | $17.6M | $17.1M | $21.4M | $12.8M | $17.4M |
| Gross margin | 74.4% | 77.2% | 79.9% | 80.5% | 61.6% | 58.4% |
| Operating margin | 27.9% | 24.2% | 27.7% | 14.6% | 8.8% | -89.3% |
| Net margin | 22.4% | 21.1% | 23.2% | 16.7% | 14.2% | -81.7% |
| Line item | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M | $18.9M | $22.4M | $20.4M | $17.5M | $18.4M | $24.3M | $21.9M |
| Gross profit | $6.8M | $10.2M | $13.1M | $13.0M | $9.8M | $10.9M | $16.1M | $15.1M |
| Operating income | -$1.2M | $126,000.00 | $2.7M | -$74.2M | $659,000.00 | $713,000.00 | $5.6M | $4.5M |
| Net income | $843,000.00 | $206,000.00 | $3.1M | -$67.3M | -$681,000.00 | $676,000.00 | $4.5M | $3.6M |
| Diluted EPS | $0.04 | $0.01 | $0.15 | -$3.35 | -$0.03 | $0.03 | $0.22 | $0.18 |
| Operating cash flow | $1.7M | -$1.3M | $5.7M | $8.1M | $5.6M | $4.2M | $6.4M | $8.7M |
| Free cash flow | $1.6M | -$1.4M | $5.6M | $7.8M | $5.3M | $4.2M | $6.4M | $8.6M |
| Gross margin | 36.6% | 54.0% | 58.5% | 64.0% | 56.4% | 59.1% | 66.5% | 69.1% |
| Operating margin | -6.2% | 0.7% | 12.1% | -364.5% | 3.8% | 3.9% | 23.2% | 20.6% |
| Net margin | 4.5% | 1.1% | 13.7% | -330.6% | -3.9% | 3.7% | 18.7% | 16.3% |
Company news
Jul 9, 2026
Jun 23, 2026
Jun 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.